SUBSCRIBE 

© 2017 Biofortis Mérieux NutriSciences

ABOUT BIOFORTIS

As part of Mérieux NutriSciences, Biofortis supports the food and health industries by conducting research projects with a unique nutrition and analytical service. A one-stop shop CRO offering innovative services including clinical assessments, microbiota-related research, sensory evaluation and consumer studies.

FIND US ON

  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.

3 Route de la Chatterie

44800 Saint-Herblain

FRANCE

Tel: +33 2 40 20 57 99

Effects of pemetrexed chemotherapy on gut microbiota and digestive inflammation in Patient-Derived Tumor Xenograft (PDX) Models

July 18, 2018

C. PENSEC, T. CARTON, S. LEUILLET, D. GUENOT,  IMODI Consortium, M. CAMPONE, H. BLOTTIERE, F. LE VACON

 

 

Introduction

 

Despite significant progress in anti-cancer treatment such as immunotherapy, chemotherapy remains a gold standard. Pemetrexed is a chemotherapeutic agent commonly used in lung cancer. This drug has a broad-spectrum effect that can induce significant side effects in patients. We have previously shown for the first time that this drug has a strong impact on the gut microbiota composition in PDX models of lung adenocarcinoma. The aim of this new study was to explore the impact of pemetrexed on the gut microbiota and gastrointestinal inflammation in resistant and sensitive mice of our PDX.

 

 

 

 

Methods

 

Upon establishment of the PDX model, mice were treated with pemetrexed for 2 weeks. Stool specimens were collected at 3 time-points. Gut microbiota composition was studied by 16S rRNA gene sequencing and the taxonomic classification of sequences was obtained using an in-house bioinformatic pipeline based on mothur software. In parallel, body weight was recorded and tissues were sampled for assessment of toxicity and inflammation.

 

 

Results

 

Pemetrexed induced a significant body weight loss after each treatment cycle reflecting toxicity as known in clinical results. A detailed analysis of the gut microbiota, intestinal permeability, and inflammation are underway. Preliminary analysis of the gut microbiota data shows an increase of Enterobacteriaceae and a decrease of Porphyromonadaceae.

 

 

Conclusion

 

A better understanding of gut microbiota alterations induced by chemotherapy could help reduce side effects. The microbiota represents an important additional “indicator” to evaluate the toxicity of pharmacological treatments that should be taken into account in the development of new molecules.

 

 

Click here to contact us if you want to receive the poster.

 

 

 

 

 

Cindy Pensec receives a Microbiome Hero award for her PhD wich she is completing at the University of Nantes, France. For 2 years she has been working on human and mice microbiota to understand the impact of chemotherapies on the gut microbiota.

 

 

 

 

Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Google+
Like this
Please reload

RECENT POSTS

Please reload

MICROBIOTA CASE STUDY

FOLLOW US

  • LinkedIn Biofortis Mérieux NutriSc.
  • Twitter Biofortis Mérieux NutriSc.
  • YouTube Biofortis Mérieux NutriSc.